-

Vetoquinol: Announcement of the Availability of the Half-Year Financial Report to June 30, 2023

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) announced today that it has made available to the public and filed with the Autorité des marchés financiers its Half-Year Financial Report to June 30, 2023.

The Half-Year Financial Report can be consulted on Vetoquinol's website at www.vetoquinol.com/en/publications in the Regulated Information section.

Next update: Q3 2023 Sales, October 26, 2023 after market close

ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the farm animals (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,497 people as of June 30, 2023.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL
Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION
Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL
Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION
Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

More News From Vetoquinol

Vetoquinol: 2025 Annual Sales

LURE, France--(BUSINESS WIRE)--Regulatory News: In an economy marked by unusual exchange rate volatility, Vetoquinol (Paris:VETO) achieved two important objectives: growth in Essential products and internalization of the manufacturing of the parasiticide range. Vetoquinol's sales for FY 2025 came to €525.7 million, up 0.2% at constant exchange rates and down 2.5% on a reported basis. Over the financial year, the company recorded historically high negative currency impacts of €14.8 million in al...

Vetoquinol: Sales at End September 2025

LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2025, Vetoquinol's (Paris:VETO) sales amounted to €384.2 million, down 3.5% on a reported basis and down 1.3% at constant exchange rates. Over this period, the Group recorded net negative currency impacts of €8.9 million in the Americas and Asia-Pacific/Rest of the World regions and an impact of - €7.7 million from the simplification of complementary ranges, mainly in Europe. Net of these two items, sales for the first nine...

Vetoquinol: 2025 Half Year Results

LURE, France--(BUSINESS WIRE)--Regulatory News: The Board of Directors of Vetoquinol SA (Paris:VETO), meeting on September 9, 2025, approved the financial statements for the first half of the 2025 financial year. The limited review report on the financial statements as of June 30, 2025, was issued by the Statutory Auditors. Vetoquinol's sales amounted to €258 million for the first six months of fiscal year 2025. Sales of Essentials products amounted to €165 million, up 4.2% at constant exchange...
Back to Newsroom